NGM Biopharmaceuticals Inc.
06/10/2021 | Press release | Distributed by Public on 06/10/2021 15:27
Submission of Matters to a Vote of Security Holders (Form 8-K)
|
Submission of Matters to a Vote of Security Holders. |
On June 8, 2021, NGM Biopharmaceuticals, Inc. (the 'Company') held its 2021 annual meeting of stockholders (the 'Annual Meeting'). The following is a brief description of each matter voted on at the Annual Meeting, as well as the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-voteswith respect to each matter. A more complete description of each matter can be found in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2021.
| 1. |
Election of Directors |
|
Director Name |
Votes For | Votes Against | Votes Withheld | Broker Non-Votes | ||||||||||||
|
Jin-LongChen, Ph.D. |
55,573,873 | 0 | 7,840,620 | 5,806,958 | ||||||||||||
|
Roger M. Perlmutter, M.D., Ph.D. |
63,369,234 | 0 | 45,259 | 5,806,958 |
The Class II director nominees were elected to hold office until the Company's 2024 annual meeting of stockholders and until their successors are duly elected and qualified.
| 2. |
Ratification of Selection of Independent Registered Public Accounting Firm |
|
Firm |
Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||||||
|
Ernst & Young LLP |
69,181,486 | 25,320 | 14,645 | 0 |
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.